

Stem Cell Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration

NCT06221787

Status	RECRUITING
Phase	Not Applicable
Sponsor	Fujian Medical University Union Hospital
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (5)

- Patients diagnosed with chloasma who meet the clinical diagnostic standards and efficacy standards (revised version) of chloasma and have skin lesions on the face.
- It is hoped that exosomes combined with 1565 non-ablative fractional laser, blue aurora or micro-needle can improve facial chloasma.
- Fully understand and understand the content and significance of this study, implementation plan, possible benefits, risks and countermeasures, rights and obligations of subjects (including privacy protection, free withdrawal), willing to participate in this clinical study and able to cooperate well, Those who signed the informed consent form.
- Exclude post-inflammatory pigmentation, malar brown-green nevus, Riehl's melanosis, pigmented lichen planus and other skin diseases.
- Subjects who agree not to use other cosmetic treatments related to the study during the study period.

Exclusion (13)

- Patients who refuse to sign the informed consent form to participate in the trial;
- Those with a history of important organ diseases, or a history of autoimmune diseases or immune dysfunction;
- Abnormal coagulation function, current use of anticoagulants, thrombophilia and history of familial genetic diseases;
- Pregnant or lactating women;
- Patients taking oral contraceptives or hormone replacement therapy during the study period or within the past 12 months;
- ... and 8 more (see full listing online)

Locations (1 total)

Affiliated Union Hospital of Fujian Medical University, Fuzhou, Fujian, China